Keywords
infections
endocarditis
Staphylococcus aureus
How to Cite
Abstract
Introduction; An increasing number of intravenous drug users are seen in now days. Intravenous drug users (IDUs) are a group of subjects who inject different drugs, generally in the extremities. This way of taking drugs, apart from leading to an addiction, on the other hand also serves as the possibility of taking or spreading infections.
The aim of this paper is to provide a brief overview of IDUs patients, who were presented to the emergency department of the infectious diseases service, and required further hospitalization, during the period January 2012 - December 2015.
Material and methods: The study is retrospective and was carried out in the emergency department of the infectious disease service and the infectious disease service as well. During the period January 2012 – December 2015, 26 patients were hospitalized in our hospital as IDUs. There were 20 male patients. The average age of the patients was 32 years. The main clinical symptoms were fever, dyspnea, chest pain, pain in the extremities, edema of the extremities, necrotic ulcers at the injection site, jaundice in the sclera, confusional state. The resulting diagnoses were viral infections (HIV/AIDS infection, viral hepatitis), septic conditions (endocarditis, fasciitis), skin infections (cellulitis, S. aureus infections), pulmonary infections.
Conclusions: Viral, bacterial and fungal infectious diseases are quite frequent among the people of this community. This is related to the way of life (poor social economic conditions, poor hygiene), risky sexual behaviors and the use of syringes from one person to another. The screening of this community is important to prevent any infectious disease.
References
Novak SP, Kral AH. Comparing Injection and Non-Injection Routes of Administration for Heroin, Methamphetamine, and Cocaine Uses in the United States. J Addict Dis. 2011;30(3):248–57.
Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1–187.
Smith PC, Page JB. Medication therapy among intravenous drug users (IDUs) with HIV infection. AIDS Patient Care STDs. 1996 Apr;10(2):101–10.
Allen VB, Bechman K, Klein JL. Bloodstream infections in Injecting drug users: A 15 year prospective single-centre study. Clin Infect Pract. 2022 Nov 1;16:100159.
De Rosa FG, Cicalini S, Canta F, Audagnotto S, Cecchi E, Di Perri G. Infective Endocarditis in Intravenous Drug Users from Italy: the Increasing Importance in HIV-infected Patients. Infection. 2007 Jun 1;35(3):154.
riedman H, Pross S, Klein TW. Addictive drugs and their relationship with infectious diseases. FEMS Immunol Med Microbiol. 2006 Aug;47(3):330–42.
McCarthy NL, Baggs J, See I, Reddy SC, Jernigan JA, Gokhale RH, et al. Bacterial Infections Associated With Substance Use Disorders, Large Cohort of United States Hospitals, 2012–2017. Clin Infect Dis. 2020 Oct 23;71(7):e37–44.
Ebright JR, Pieper B. Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am. 2002 Sep;16(3):697–712.
Baltes A, Akhtar W, Birstler J, Olson-Streed H, Eagen K, Seal D, et al. Predictors of skin and soft tissue infections among sample of rural residents who inject drugs. Harm Reduct J. 2020 Dec 2;17(1):96.
Farhadian N, Karami Matin B, Farnia V, Zamanian MH, Najafi F, Farhadian M. The prevalence of people who inject drugs among those with HIV late presentation: a meta-analysis. Subst Abuse Treat Prev Policy. 2022 Feb 10;17(1):11.
Gokengin D, Oprea C, Begovac J, Horban A, Zeka AN, Sedlacek D, et al. HIV care in Central and Eastern Europe: How close are we to the target? Int J Infect Dis. 2018 May 1;70:121–30.
Mortality among people who inject drugs: a systematic review and meta-analysis - PMC. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605003/
Nguemeni Tiako MJ, Mori M, Bin Mahmood SU, Shioda K, Mangi A, Yun J, et al. Recidivism Is the Leading Cause of Death Among Intravenous Drug Users Who Underwent Cardiac Surgery for Infective Endocarditis. Semin Thorac Cardiovasc Surg. 2019 Mar 1;31(1):40–5.
Glynn JR, Moss PAH. Systematic analysis of infectious disease outcomes by age shows lowest severity in school-age children. Sci Data. 2020 Oct 15;7(1):329.
Mertz D, Viktorin N, Wolbers M, Laifer G, Leimenstoll B, Fluckiger U, et al. Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis. BMC Infect Dis. 2008 Apr 3;8:42.
Mosseler K, Materniak S, Brothers TD, Webster D. Epidemiology, Microbiology, and Clinical Outcomes Among Patients With Intravenous Drug Use-Associated Infective Endocarditis in New Brunswick. CJC Open. 2020 Sep 1;2(5):379–85.
Straw S, Baig MW, Gillott R, Wu J, Witte KK, O’regan DJ, et al. Long-term Outcomes Are Poor in Intravenous Drug Users Following Infective Endocarditis, Even After Surgery. Clin Infect Dis. 2020 Jul 27;71(3):564–71.
Klester E, Klester K, Igor B. Septic pulmonary embolism in intravenous drug users. Eur Respir J. 2017;50(suppl 61). Available from: https://erj.ersjournals.com/content/50/suppl_61/PA2353
Galili Y, Lytle M, Carlan S, Madruga M. Bilateral Pneumothoraces: A Rare Complication of Septic Pulmonary Emboli in Intravenous Drug Abusers. Am J Case Rep. 2018 Jul 14;19:829–32.
Colville T, Sharma V, Albouaini K. Infective endocarditis in intravenous drug users: a review article. Postgrad Med J. 2016 Feb 1;92(1084):105–11.
Ji Y, Kujtan L, Kershner D. Acute endocarditis in intravenous drug users: a case report and literature review. J Community Hosp Intern Med Perspect. 2012 Apr 30;2(1):10.3402/jchimp.v2i1.11513.
Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, et al. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat Med. 2021 Dec;27(12):2085–98.
Li J, Wang J, Tian K, Wang Y, Zhang L, Huang H. Epidemiology of hepatitis B, C, D and G viruses and cytokine levels among intravenous drug users. J Huazhong Univ Sci Technol Med Sci Hua Zhong Ke Ji Xue Xue Bao Yi Xue Ying Wen Ban Huazhong Keji Daxue Xuebao Yixue Yingdewen Ban. 2006;26(2):221–4.
Grassi A, Ballardini G. Hepatitis C in injection drug users: It is time to treat. World J Gastroenterol. 2017 May 28;23(20):3569–71.
Bruggmann P, Blach S, Deltenre P, Fehr J, Kouyos RD, Lavanchy D, et al. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Med Wkly. 2017 Nov 8;(45). Available from: https://smw.ch/article/doi/smw.2017.14543
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.